AAL

FDA Buzz Sends Health and Wellness Stock Surging

Options traders are swarming HIMS in response

Managing Editor
Oct 14, 2024 at 11:03 AM
facebook X logo linkedin


Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA). The FDA announced it will allow compounding pharmacies to create and sell their own version of Eli Lilly's (LLY) weight-loss drug Mounjaro.

In response, HIMS is enjoying a healthy bull gap, pacing toward its highest close since July, and has now broken above the resistant $20 level. The stock sports a 230% year-over-year gain, but still remain a ways off its mid-June peak.

Over in the options pits, traders are moving in, with 18,000 calls across the tape so far today, volume that's three times the average intraday amount. Most popular is the October 20 call, as well as the November 21 and 23 calls.

A short squeeze could help HIMS return to those summer highs. Short interest dropped 11.7% over the past month, yet the 24.76 million shares sold short still accounts for 14% of the stock's total available float.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.